Leptomeningeal Carcinomatosis after Major Remission to Taxane-based Front-line Therapy in Patients with Advanced Breast Cancer

Author： Kosmas C.   Malamos N.A.   Tsavaris N.B.   Stamataki M.   Stefanou S.   Gregoriou A.   Rokana S.   Vartholomeou M.   Antonopoulos M.J.  

Publisher： Springer Publishing Company

ISSN： 0167-594X

Source： Journal of Neuro-Oncology, Vol.56, Iss.3, 2002-02, pp. : 265-273

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Can the Status of the Breast and Ovarian Cancer Susceptibility Gene 1 Product (BRCA1) Predict Response to Taxane-Based Cancer Therapy?

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 9, Iss. 5, 2009-06 ,pp. : 543-549

Bentham Science Publishers

Access to resources Recommend Favorite

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy

By Hurvitz Sara   Dalenc Florence   Campone Mario   O’Regan Ruth   Tjan-Heijnen Vivianne   Gligorov Joseph   Llombart Antonio   Jhangiani Haresh   Mirshahidi Hamid   Tan-Chiu Elizabeth   Miao Sara   El-Hashimy Mona   Lincy Jeremie   Taran Tetiana   Soria Jean-Charles   Sahmoud Tarek   André Fabrice  

Breast Cancer Research and Treatment, Vol. 141, Iss. 3, 2013-10 ,pp. : 437-446

Springer Publishing Company

Access to resources Recommend Favorite

BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy

By Foedermayr Mathilde   Sebesta Miriam   Rudas Margaretha   Berghoff Anna   Promberger Regina   Preusser Matthias   Dubsky Peter   Fitzal Florian   Gnant Michael   Steger Guenther   Weltermann Ansgar   Zielinski Christoph   Zach Otto   Bartsch Rupert  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 4, 2014-04 ,pp. : 771-778

Springer Publishing Company

Access to resources Recommend Favorite

Phase II Trial of Topotecan, Carboplatin, and Paclitaxel as Front-Line Therapy in Suboptimal Advanced Epithelial Ovarian Cancer

By Bolis G.   Scarfone G.   Villa A.   Parazzini F.  

Gynecologic Oncology, Vol. 81, Iss. 2, 2001-05 ,pp. : 331-333

Elsevier

Access to resources Recommend Favorite

Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens

By Kosmas C.   Tsavaris N.   Panopoulos C.   Vadiaka M.   Stavroyianni N.   Kourelis T.   Malamos N.   Antonopoulos M.   Kalofonos H.P.  

European Journal of Cancer, Vol. 37, Iss. 8, 2001-05 ,pp. : 972-978

Elsevier

Access to resources Recommend Favorite